Seven Innovent drugs and indications added to China’s 2026 NRDL

The four first-time additions are mazdutide, PECONDLE® (picankibart), TABOSUN® (ipilimumab N01) and Vanflyta® (quizartinib). TYVYT® (sintilimab) and Jaypirca® (pirtobrutinib) gained coverage for additional indications, while SINTBILO® (tafolecimab) was renewed, Innovent said.

The newly covered uses include mazdutide for adults with type 2 diabetes and picankibart for adults with moderate to severe plaque psoriasis who are eligible for systemic therapy. Ipilimumab N01, used with sintilimab, was added for neoadjuvant treatment of resectable stage IIB–III MSI-H or dMMR colon cancer. Quizartinib was included for newly diagnosed FLT3-ITD-positive acute myeloid leukemia.

Newly reimbursed indications for sintilimab include its use with ipilimumab N01 in the specified colon cancer setting, and with fruquintinib for certain patients with locally advanced or metastatic renal cell carcinoma after prior VEGFR tyrosine kinase inhibitor therapy. Pirtobrutinib coverage now includes adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least one prior systemic treatment that included a BTK inhibitor.

Innovent Founder, Chairman and CEO Dr. Michael Yu said the seven additions cover oncology, cardiovascular and metabolic diseases, and autoimmune conditions. He said the company now has 17 innovative medicines covered by the NRDL, which have cumulatively benefited more than 20 million patients. The figures and potential improvements in access were reported by the company.